Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30259326 | 0.86 | MAPKAPK2 (0.37) | ALDH1A1CDK2MAPKAPK2 | |
| SCHEMBL17204459 | 0.86 | MAPKAPK2 (0.37) | ALDH1A1CDK2MAPKAPK2 | |
| SCHEMBL20977360 | 0.81 | ALDH1A1 (0.33) | ALDH1A1CDK2MAPKAPK2CSNK1A1CLK4 | |
| SCHEMBL12791033 | 0.80 | — | — | |
| SCHEMBL24367881 | 0.78 | CDK2 (0.33) | CDK2CSNK1A1CLK4 | |
| SCHEMBL26127401 | 0.77 | MAPKAPK2 (0.35) | ALDH1A1CDK2MAPKAPK2 | |
| SCHEMBL24323977 | 0.77 | TLR7 (0.38) | ALDH1A1CDK2MAPKAPK2 | |
| SCHEMBL30588906 | 0.77 | MAPKAPK2 (0.35) | ALDH1A1CDK2MAPKAPK2 | |
| SCHEMBL19457843 | 0.75 | CDK2 (0.31) | CDK2 | |
| SCHEMBL26122570 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089597-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2022-03-24 | — | — | US | disclosed |
| US-20210309663-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| US-20210309663-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | CADILA HEALTHCARE LIMITED (IN) | 2021-09-23 | — | — | US | disclosed |
| US-10975080-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| US-10975080-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| CN-112543757-A | Condensed azaheteroaryl compounds having antibacterial activity against tubercle bacillus | 卡迪拉保健有限公司 | 2021-03-23 | — | — | CN | disclosed |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-06-20 | — | — | US | disclosed |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-06-20 | — | — | US | disclosed |
| EP-3310779-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2019-05-08 | — | — | EP | disclosed |
| WO-2016203404-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203404-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| US-20110059118-A1 | INHIBITORS OF JAK | DE VICENTE FIDALGO JAVIER | 2011-03-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2183243-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | Pfizer Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089597-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN5 | ALDH1A1 3953/4885CDK2 991/4885MAPKAPK2 727/4885 |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | ALDH1A1 615/4885CDK2 182/4885MAPKAPK2 93/4885 |
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | DPEP1, SAT1, PEPD | ALDH1A1 152/4885CDK2 850/4885MAPKAPK2 3059/4885 |
| US-10975080-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN1, PTPN3, PTPN5 | ALDH1A1 4341/4885CDK2 623/4885MAPKAPK2 442/4885 |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN5 | ALDH1A1 3953/4885CDK2 991/4885MAPKAPK2 727/4885 |
| US-20110059118-A1 | INHIBITORS OF JAK | JAK1, JAK3, JAK2 | ALDH1A1 4659/4885CDK2 1218/4885MAPKAPK2 738/4885 |
| US-20210309663-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN5 | ALDH1A1 3953/4885CDK2 991/4885MAPKAPK2 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.